These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 25871395)

  • 1. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.
    Kaluzova M; Bouras A; Machaidze R; Hadjipanayis CG
    Oncotarget; 2015 Apr; 6(11):8788-806. PubMed ID: 25871395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.
    Bouras A; Kaluzova M; Hadjipanayis CG
    J Neurooncol; 2015 Aug; 124(1):13-22. PubMed ID: 25981803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.
    Hadjipanayis CG; Machaidze R; Kaluzova M; Wang L; Schuette AJ; Chen H; Wu X; Mao H
    Cancer Res; 2010 Aug; 70(15):6303-12. PubMed ID: 20647323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas.
    Freeman AC; Platt SR; Holmes S; Kent M; Robinson K; Howerth E; Eagleson J; Bouras A; Kaluzova M; Hadjipanayis CG
    J Neurooncol; 2018 May; 137(3):653-663. PubMed ID: 29350351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.
    Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW
    Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro.
    Chen HL; Hsu FT; Kao YJ; Liu HS; Huang WZ; Lu CF; Tsai PH; Ali AAA; Lee GA; Chen RJ; Chen CY
    J Nanobiotechnology; 2017 Nov; 15(1):86. PubMed ID: 29166921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
    Álvarez-Vázquez A; San-Segundo L; Cerveró-García P; Flores-Hernández R; Ollauri-Ibáñez C; Segura-Collar B; Hubert CG; Morrison G; Pollard SM; Lathia JD; Sánchez-Gómez P; Tabernero A
    Neuro Oncol; 2024 Jul; 26(7):1230-1246. PubMed ID: 38507464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
    Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
    Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glioma stem cells enhances anti-tumor effect of boron neutron capture therapy.
    Sun T; Li Y; Huang Y; Zhang Z; Yang W; Du Z; Zhou Y
    Oncotarget; 2016 Jul; 7(28):43095-43108. PubMed ID: 27191269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma Therapy Using Codelivery of Cisplatin and Glutathione Peroxidase Targeting siRNA from Iron Oxide Nanoparticles.
    Zhang Y; Fu X; Jia J; Wikerholmen T; Xi K; Kong Y; Wang J; Chen H; Ma Y; Li Z; Wang C; Qi Q; Thorsen F; Wang J; Cui J; Li X; Ni S
    ACS Appl Mater Interfaces; 2020 Sep; 12(39):43408-43421. PubMed ID: 32885649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
    Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
    PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
    Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
    J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
    Kim JS; Shin DH; Kim JS
    J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
    Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
    J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cells.
    Wu N; Liu J; Zhao X; Yan Z; Jiang B; Wang L; Cao S; Shi D; Lin X
    Tumour Biol; 2015 Dec; 36(12):9667-76. PubMed ID: 26150336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma.
    Jiang W; Finniss S; Cazacu S; Xiang C; Brodie Z; Mikkelsen T; Poisson L; Shackelford DB; Brodie C
    Oncotarget; 2016 Aug; 7(35):56456-56470. PubMed ID: 27486821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.